AZD8055
目录号:S1555 Purity: 99.84%
AZD8055是一种新型的,ATP竞争性mTOR抑制剂,在MDA-MB-468 细胞中IC50为0.8 nM,与作用于PI3K亚型和ATM/DNA-PK相比,具有优异的选择性(约1000倍)。AZD8055可诱导半胱天冬酶依赖的凋亡和自噬。Phase 1。
CAS: 1009298-09-2
客户使用Selleck的AZD8055发表文献255篇
- Gastroenterology, 2024 S0016-5085(24)00062-3
- Nat Neurosci, 2023 none
- Immunity, 2022 55(1):159-173.e9
- Nature, 2021 591(7849):288-292
- Immunity, 2021 S1074-7613(21)00069-8
- Nat Med, 2020 10.1038/s41591-020-0986-1
- Nat Med, 2019 25(5):838-849
- Nature, 2019 574(7777):268-272
- Cancer Cell, 2019 35(5):752-766
- Cell, 2018 172(1-2):373-386
- Cell Stem Cell, 2018 22(3):369-383
- Nat Cell Biol, 2018 20(4):465-478
- Nat Med, 2017 23(2):200-212
- Cancer Cell, 2017 31(5):635-652
- Cell Stem Cell, 2017 20(2):177-190
- Nat Cell Biol, 2016 18(5):527-39
- Nat Med, 2015 10.1038/nm.3855
- Cancer Cell, 2015 27(1):97-108
- Cancer Cell, 2015 27(4):533-46
- J Hematol Oncol, 2015
- Cancer Discov, 2015 5(3):255-63
- Cancer Discov, 2015 5(3):245-54
- Mol Cancer, 2013 12:81
- Blood, 2013 121(18):3619-30
- Nat Commun, 2024 15(1):2581
- Nat Commun, 2024 15(1):7675
- J Clin Invest, 2024 134(16)e168393
- Cell Rep, 2024 43(9):114710
- J Cell Mol Med, 2024 28(9):e18374
- J Biol Chem, 2024 S0021-9258(24)00057-7
- J Cell Sci, 2024 137(9)jcs262116
- Exp Mol Pathol, 2024 138:104916
- BioRxiv, 2024 10.1101/2021.07.29.454319
- Cancer Res, 2023 83(2):316-331
- Cell Rep, 2023 42(1):111990
- Mol Oncol, 2023 none
- Cancers (Basel), 2023 15(4)1158
- Cancers (Basel), 2023 15(6)1737
- Nat Cardiovasc Res, 2023 2(6):550-571
- ACS Bio Med Chem Au, 2023 3(3):283-294
- Nat Chem Biol, 2022 10.1038/s41589-022-00996-7
- Small, 2022 18(4):e2103552
- Theranostics, 2022 12(14):6395-6408
- Metabolism, 2022 130:155165
- Cell Death Dis, 2022 13(12):1046
- J Cell Biol, 2022 221(6)e202105112
- Biochem Pharmacol, 2022 200:115045
- iScience, 2022 25(3):103881
- iScience, 2022 25(10):105182
- Am J Cancer Res, 2022 12(4):1535-1555
- Cancers (Basel), 2022 14(6)1575
- Chem Biol Interact, 2022 364:110060
- J Biol Chem, 2022 S0021-9258(22)00730-X
- Drug Des Devel Ther, 2022 16:3817-3828
- Sci Rep, 2022 12(1):17665
- Sci Rep, 2022 12(1):5718
- J Cell Sci, 2022 135(23)jcs260313
- Microbiol Spectr, 2022 10(1):e0200721
- Front Cardiovasc Med, 2022 9:895916
- Bull Exp Biol Med, 2022 173(3):366-370
- bioRxiv, 2022 10.1101/2022.03.06.483170
- Nat Commun, 2021 12(1):1589
- Nat Commun, 2021 12(1):1920
- Nat Chem Biol, 2021 10.1038/s41589-021-00751-4
- Cancer Res, 2021 81(22):5652-5665
- Haematologica, 2021 10.3324/haematol.2021.278743
- Cell Death Dis, 2021 12(11):1044
- Cell Rep, 2021 34(11):108870
- Cell Rep, 2021 35(1):108940
- Elife, 2021 10e65962
- Plant Physiol, 2021 kiab589
- Arch Pharm Res, 2021 10.1007/s12272-021-01358-y
- J Clin Endocrinol Metab, 2021 dgab020
- Mol Cancer Ther, 2021 molcanther.0224.2021
- Am J Physiol Cell Physiol, 2021 321(6):C964-C977
- Front Cell Dev Biol, 2021 9:662868
- Front Microbiol, 2021 12:596874
- J Biol Chem, 2021 S0021-9258(21)00418-X
- Front Oncol, 2021 11:648809
- J Pharm Biomed Anal, 2021 208:114436
- Oncol Lett, 2021 21(4):269
- Sci Adv, 2021 7(40):eabj2485
- Biomed Chromatogr, 2021 e5190
- STAR Protoc, 2021 2(1):100300
- Nat Commun, 2020 11(1):3627
- Nat Commun, 2020 11(1):4684
- Dev Cell, 2020 55(3):298-313.e10
- Clin Cancer Res, 2020 10.1158/1078-0432
- J Exp Clin Cancer Res, 2020 9;39(1):107
- Cell Rep, 2020 31(12):107810
- Cell Rep, 2020 32(3):107933
- Br J Cancer, 2020 22
- Eur J Cancer, 2020 126:93-103
- J Cell Biol, 2020 219(2)
- Front Immunol, 2020 11:572960
- Mol Oncol, 2020 10.1002/1878-0261.12673
- J Invest Dermatol, 2020 S0022-202X(20)31981-3
- J Bone Miner Res, 2020 10.1002/jbmr.4176
- Cancer, 2020 10.1002/cncr.33071
- Mol Cancer Ther, 2020 5;molcanther.1131.2019
- Mol Cancer Ther, 2020 19(3):882-894
- Int Immunopharmacol, 2020 81:106241
- Aging (Albany NY), 2020 12(19):19022-19044
- J Biol Chem, 2020 22;295(21):7418-7430
- Sci Rep, 2020 4;10(1):4025
- Cell Cycle, 2020 1-15
- J Cell Sci, 2020 133(14)jcs246306
- Biosci Rep, 2020 30;40(4):BSR20200905
- J Cancer, 2020 15;11(12):3492-3501
- BMC Cancer, 2020 20(1):724
- Kaohsiung J Med Sci, 2020 10.1002/kjm2.12319
- Biochem Biophys Res Commun, 2020 23;S0006-291X(20)30951-7
- G3 (Bethesda), 2020 4;10(5):1585-1597
- Mol Cell, 2019 10.1016/j.molcel.2019.10.016
- Autophagy, 2019 10.1080/15548627.2019.1660545
- Autophagy, 2019 15(3):543-557
- Clin Cancer Res, 2019 25(21):6429-6442
- Clin Cancer Res, 2019 25(16):5107-5121
- Curr Biol, 2019 29(5):737-749
- Cell Death Dis, 2019 10(8):563
- Cell Rep, 2019 27(12):3696-3708.e5
- Cell Chem Biol, 2019 26(3):366-377
- JCI Insight, 2019 4(20)124164
- Sci Signal, 2019 12(612)
- Cell Mol Gastroenterol Hepatol, 2019 8(1):21-36
- Cancer Gene Ther, 2019 10.1038/s41417-019-0117-7
- Cancer Biol Med, 2019 16(1):66-83
- J Neurosci, 2019 39(27):5255-5268
- Am J Cancer Res, 2019 9(9):1922-1937
- Cancers (Basel), 2019 11(10)
- Sci Rep, 2019 9(1):30
- Sci Rep, 2019 9(1):9805
- Biochem J, 2019 476(20):3081-3107
- Front Physiol, 2019 10:167
- Biomed Res Int, 2019 2019:5196028
- J Exp Med, 2018 215(1):159-175
- Cancer Res, 2018 78(12):3176-3189
- Cancer Res, 2018 78(15):4396-4410
- Cell Death Dis, 2018 9(11):1063
- Acta Pharmacol Sin, 2018 39(8):1338-1346
- J Mol Cell Biol, 2018 10(4):331-340
- Cell Signal, 2018 44:127-137
- Sci Rep, 2018 8(1):10784
- Life Sci Alliance, 2018 1(3):e201800029
- Front Genet, 2018 9:690
- PLoS One, 2018 13(8):e0200725
- Med Sci Monit, 2018 24:2735-2743
- Oncol Lett, 2018 16(4):4561-4566
- Oncol Lett, 2018 16(1):632-642
- Nat Commun, 2017 8(1):1090
- Nat Commun, 2017 8(1):2207
- Nucleic Acids Res, 2017 45(16):9654-9678
- Mol Syst Biol, 2017 13(1):905
- Cell Syst, 2017
- Cell Rep, 2017 20(10):2341-2356
- Cell Commun Signal, 2017 10.1186/s12964-017-0164-3
- Oncogene, 2017 36(15):2074-2084
- Oncogene, 2017 36(26):3651-3660
- Elife, 2017 6e29353
- Sci Signal, 2017 10(507)eaam7550
- PLoS Pathog, 2017 13(4):e1006344
- Mol Cancer Ther, 2017 16(1):102-115
- Oncotarget, 2017 8(4):5992-6002
- Oncotarget, 2017 8(1):979-987
- Oncotarget, 2017 8(25):41422-41431
- Biochim Biophys Acta Mol Cell Res, 2017 1864(10):1554-1565
- Sci Rep, 2017 7(1):1535
- Sci Rep, 2017 7(1):1994
- PLoS One, 2017 12(7):e0181243
- J Pharm Biomed Anal, 2017 145:473-481
- Anticancer Res, 2017 37(3):1083-1090
- Nat Chem Biol, 2016 12(1):22-8
- Genome Biol, 2016 17(1):149
- EMBO J, 2016
- Mol Oncol, 2016 10(1):101-12
- Mol Oncol, 2016 10(4):538-52
- Front Plant Sci, 2016 7:1746
- Oncotarget, 2016 7(44):71211-71222
- Oncotarget, 2016 7(4):3947-65
- Aging (Albany NY), 2016 8(2):231-44
- Aging (Albany NY), 2016 8(12):3535-3551
- Cell Signal, 2016 28(4):284-93
- J Biol Chem, 2016 291(12):6262-71
- Sci Rep, 2016
- J Immunol, 2016 196(10):4390-9
- PLoS One, 2016 11(4):e0154564
- Biochem Biophys Res Commun, 2016 478(4):1515-20
- Int J Endocrinol, 2016 2016:5286972
- Autophagy, 2015 11(2):285-97
- Cancer Res, 2015 75(20):4398-406
- Cell Rep, 2015 11(3):446-59
- Sci Signal, 2015 8(375):ra42
- J Med Chem, 2015 58(16):6559-73
- Clin Sci (Lond), 2015 128(8):517-26
- Int J Mol Sci, 2015 16(2):3267-82
- Oncotarget, 2015 6(11):8722-35
- Oncotarget, 2015 6(7):5118-33
- Mol Cancer Res, 2015 13(1):120-9
- Mol Cancer Res, 2015 13(2):223-30
- Am J Physiol Endocrinol Metab, 2015 309(2):E142-53
- Cell Signal, 2015 27(8):1557-68
- J Biol Chem, 2015 10.1074/jbc.C114.627778
- Cell Signal, 2015 27(11):2191-200
- Stem Cells Int, 2015 2015:561404
- Biochem J, 2015 465(2):227-38
- J Chromatogr A, 2015 1388:267-73
- J Cancer, 2015 6(12):1195-205
- PLoS One, 2015 10(11):e0143357
- PLoS One, 2015 10(7):e0131400
- Cancer Biol Ther, 2015
- Proteomics, 2015 10.1002/pmic.201400586
- Nat Commun, 2014 5:3384
- J Clin Invest, 2014 10.1172/JCI73935
- Autophagy, 2014 10(6):1120-36
- Clin Cancer Res, 2014 20(22):5756-67
- Leukemia, 2014 28(5):1092-102
- Cancer Res, 2014 74(10):2846-56
- Cancer Res, 2014 74(14):3947-58
- Mol Metab, 2014 3(6):630-41
- Sci Signal, 2014 7(349):ra102
- Mol Cell Proteomics, 2014 13(6):1429-38
- Antioxid Redox Sign, 2014 20(9):1382-95
- J Invest Dermatol, 2014 134(4):1108-1118
- Int J Cancer, 2014 10.1002/ijc.28880
- Oncotarget, 2014
- Oncotarget, 2014 5(21):10732-44
- Oncotarget, 2014 5(21):10503-17
- Oncotarget, 2014 5(15):6015-27
- Oncotarget, 2014 5(18):8737-49
- Mol Cell Biol, 2014 34(22):4088-103
- Mol Cell Biol, 2014 34(13):2517-32
- Am J Cancer Res, 2014
- Am J Cancer Res, 2014 4(6):824-837
- Oncol Rep, 2014 31(2):649-56
- Biochem J, 2014 463(3):413-27
- PLoS One, 2014 9(12):e113555
- Mol Reprod Dev, 2014 81(7):655-65
- EMBO J, 2013 28;32(17):2377-91
- Cancer Res, 2013 73(11):3402-11
- Am J Transplant, 2013 13(8):2035-43
- Sci Signal, 2013 6(271):ra25
- Mol Oncol, 2013 33:404-18
- Mol Cancer Ther, 2013 13(1):37-48
- Mol Cancer Ther, 2013
- J Hypertens, 2013 31(2):303-11
- J Biol Chem, 2013 288(49):35287-96
- Onco Targets Ther, 2013 6:1373-84
- PLoS One, 2013 8(2):e56567
- Mol Biol Cell, 2013 24(23):3736-45
- Biochem Biophys Res Commun, 2013 440(4):701-6
- Cancer Chemother Pharmacol, 2013 71(5):1297-307
- Oncol Lett, 2013 5(2):717-721
- Autophagy, 2012 9(1):74-92
- Biochem Pharmacol, 2012 83(9):1183-94
- Exp Neurol, 2012 233(2):799-806
化学信息&溶解度
分子量 | 465.54 |
分子式 | C25H31N5O4 |
CAS号 | 1009298-09-2 |
Smiles | CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 93 mg/mL ( 199.76 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 93 mg/mL Water : Insoluble DMSO : 93 mg/mL ( 199.76 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 20 mg/mL Water : Insoluble DMSO : 93 mg/mL ( 199.76 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 3.5 mg/mL Water : Insoluble DMSO : 93 mg/mL ( 199.76 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 93 mg/mL Water : Insoluble DMSO : 50 mg/mL ( 107.4 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 10 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
4%DMSO
30%PEG300
66%ddH2O
浓度:5mg/ml
(10.74mM)
操作示例:以 1 mL 工作液为例,取40μL125mg/ml的澄清DMSO储备液加到300μL PEG 300中,混合均匀使其澄清;然后继续加入660μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。